Game Changer: TrialNet Is First to Delay Type 1 Diabetes Onset Game Changer: TrialNet Is First to Delay Type 1 Diabetes Onset

Teplizumab, an investigational anti-CD3 monoclonal antibody, delayed the onset of type 1 diabetes for 2 years in patients in the TrialNet study. Experts urge caution but admit result is"terrific."Medscape Medical News
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Diabetes & Endocrinology News Source Type: news